Current Report Filing (8-k)
November 14 2022 - 5:45PM
Edgar (US Regulatory)
false
0001716621
0001716621
2022-11-14
2022-11-14
0001716621
dei:FormerAddressMember
2022-11-14
2022-11-14
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 14, 2022
Ra Medical Systems, Inc.
(Exact name of registrant as specified in its charter)
|
Delaware |
|
001-38677 |
|
38-3661826 |
|
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
5857 Owens Drive, Suite 300
Carlsbad, California 92009
(Address of principal executive offices, including zip code)
(760) 804-1648
(Registrant’s telephone number, including area code)
2070 Las Palmas Drive, Carlsbad, California 92011
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
☒
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☒ |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
|
Trading
Symbol(s) |
|
Name of each exchange on which registered |
|
Common Stock, par value $0.0001 per share |
|
RMED |
|
NYSE American |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition.
On November 14, 2022, Ra Medical Systems, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2022. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this current report shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission, whether filed before or after the date hereof regardless of any general incorporation language in any such filing, unless the registrant expressly sets forth in such filing that such information is to be considered "filed" or incorporated by reference therein.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
RA MEDICAL SYSTEMS, INC. |
|
|
|
|
|
|
|
Date: November 14, 2022 |
|
By: |
|
/s/ Brian Conn |
|
|
|
|
|
Brian Conn |
|
|
|
|
|
Interim Chief Financial Officer |
|
|
|
|
|
(Principal Financial and Accounting Officer) |
Ra Medical Systems (AMEX:RMED)
Historical Stock Chart
From Oct 2024 to Nov 2024
Ra Medical Systems (AMEX:RMED)
Historical Stock Chart
From Nov 2023 to Nov 2024
